NCT05895942

Exploring the Molecular Mechanism Based on KIT Mutation

Exploring the Molecular Mechanism of Secondary Resistance to Imatinib in Gastrointestinal Stromal Tumors Based on KIT Mutation

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 190 (estimated)
• Sponsor: Xijing Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: —

Summary

Imatinib remains suboptimal for recurrence/metastasis and unresectable GIST response rates. With the maturity of genomics and metabolomics, people gradually realize the role of gut microbiota in tumor therapy. The gut microbiota may affect tumor treatment by regulating the tumor microenvironment or the host immune system, and some bacteria can fight tumors by activating the immune system. Growing evidence shows that the effect of tumor therapy is related to the composition of the gut microbiota of patients, and that the composition of the gut microbiota of patients sensitive to drug treatment has certain characteristics, and these characteristics may be used as biomarkers to predict the prognosis of treatment. At present, it remains unclear whether the efficacy of imatinib is related to the gut microbiota in GIST patients. Therefore, precise mining of microbial information and the development of reasonable and feasible microbial interventions are expected to optimize the treatment strategy of GIST to a large extent and provide a basis for individualized treatment of advanced GIST.

Detailed description

Taking Chinese patients with unresectable C-kit9/11-mutated GIST as the research object, the treatment effect was observed after standardized treatment with imatinib mesylate. To explore the relationship between intestinal flora and the efficacy of imatinib treatment, to find new biomarkers to predict the efficacy of imatinib, and to provide reference for individualized treatment of imatinib

Conditions

• GIST

Interventions

Type	Name	Description
DRUG	Imatinib	The control group, before and after imatinib treatment, and patients with different efficacy of imatinib treatment were collected, and the correlation analysis was performed to screen the key flora and metabolites that affect the efficacy of imatinib

Timeline

• Start date: 2021-09-10
• Primary completion: 2024-09-10
• Completion: 2025-09-10
• First posted: 2023-06-09
• Last updated: 2023-06-09

Locations

1 site across 1 country: China